IFNA17 and melanoma: For example, in 2020, a phase I/II clinical trial showed that adoptive cell therapy with tumor-reactive T cells in combination with a mild IFNα regimen could increase the median overall survival in metastatic refractory melanoma patients from non-responders (7 months) to responders (36 months) [10].